J&J Accelerates COVID-19 Vaccine Development, Targeting Phase III Start In September
Executive Summary
Phase I/IIa trial is poised to start in July versus a prior target of September, with a Phase III start targeted for late September. J&J also reported 2.1% pharma sales growth, reflecting an impact from COVID-19.